Physician profile
Mark T Simon
NPI 1053307694
$18,015.60
in general payments reported to CMS, 2019-2025
65 companies · $2,687 in 2025
The $2,687 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,579 · 2020: $2,432 · 2021: $2,506 · 2022: $2,906 · 2023: $2,523 · 2024: $2,383 · 2025: $2,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,482 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,482.13 |
| Education | $110.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,131.82 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,832.96 | 2020-2025 | Vraylar, Ubrelvy, Linzess |
| Pfizer INC. | $1,402.76 | 2019-2025 | |
| Lilly USA, LLC | $1,120.20 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $822.48 | 2019-2025 | Ofev, Jardiance |
| Novo Nordisk INC | $787.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Teva Pharmaceuticals USA, INC. | $622.51 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $608.38 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $584.01 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $557.51 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $487.21 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $484.42 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Janssen Pharmaceuticals, INC | $439.87 | 2019-2025 | Spravato |
| Esperion Therapeutics, INC. | $421.18 | 2021-2025 | Nexletol |
| Exact Sciences Corporation | $401.91 | 2023-2025 | Cologuard Collection Kit |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.